Contact

Category: Press Releases

ASM Journal Article Highlights RP557 Efficacy in Candidiasis

SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announces the publication of a research study demonstrating remarkable efficacy for its drug candidate RP557 in recurrent vaginal fungal infections. The study, entitled ‘Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment,’ appears in the August 2019 issue of Antimicrobial Agents and Chemotherapy, a publication of the American Society […]

Riptide Presents Promising Late Preclinical Results at IPF Summit

SAN DIEGO, CA. – Riptide Bioscience President Dr. George Martin today delivered a poster presentation at the 2019 IPF Summit, the largest industry event specifically focused on translational programs in Idiopathic Pulmonary Fibrosis. Dr. Martin’s presentation was entitled ‘Synthetic Peptides Reprogram M2/Fibrotic Macrophages to M1, Preventing Bleomycin Induced Lung and Skin Fibrosis.’ Dr. Martin focused […]

Riptide Addresses International Workshop on Scleroderma Research

CAMBRIDGE, UK – Dr. Henry Lopez, Executive Vice President of Riptide Bioscience, today addressed the International Workshop on Scleroderma Research (IWSR). The Workshop, co-sponsored by the University of Pittsburgh and University College London, is the largest international meeting devoted to pathogenic mechanisms in systemic scleroderma (SSc). Riptide Bioscience was one of two biotech companies invited […]

Riptide Bioscience Announces NCI Contract to Evaluate RP Drug Candidates in Combination with Radiotherapy

SAN FRANCISCO, CA. – Henry Lopez, Executive Vice President of Riptide Bioscience, Inc., today announced the execution of a Cooperative Research and Development Agreement (NCI CRADA #03045) with the National Cancer Institute (NCI), part of the National Institutes of Health. The agreement carries a three-year term and is entitled, Evaluation of Riptide Bioscience’s Proprietary Peptide […]

Riptide Bioscience Awarded NIH Grant to Address Diabetic Ulcers

SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announced that it has been awarded a $227,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to develop peptide therapeutics targeting diabetic foot ulcers. According to NIDDK, diabetes afflicts 30 million people in the United States. Ulceration is among the most serious results […]

Riptide Antimicrobial Research Highlighted on Defense Department Website

SAN FRANCISCO, CA. – Riptide’s research supported by the US Department of Defense Medical Research and Development Program (DMRDP) today became the featured program on the Congressionally Directed Medical Research Programs (CDMRP) website. CDMRP cites examples of outstanding research on its website and in the CDMRP Annual Report. A summary of this Riptide research is […]

Riptide Addresses JPC-2 Military Expert Review Committee

BETHESDA, MD. – On May 29, Riptide Principal Scientist Dr. L. Edward Clemens gave an invited presentation to the JPC-2 Military Infections Disease Research Program (MIDRP) Expert Review Committee, a part of the Congressionally Directed Medical Research Programs (CDMRP). The title of the presentation was: ‘Evaluation of Novel Antimicrobial Peptides as Topical Anti-Infectives with Broad […]

Riptide Scientific Officer Addresses International Biotechnology and Research Conference

ROME, ITALY – Riptide Executive Vice President Dr. Henry Lopez gave today’s keynote address to the ‘Biotech 2018’ International Biotechnology and Research Conference. The Biotech 2018 conference is hosted by a collaboration among the DGFI (German Society for Immunology), the University of Siena, the Swiss Biotechnology Association, and Madridge International Conferences. The conference highlights the […]

RP-185 Featured in 2018 AACR Presentation

SAN FRANCISCO, CA. – Riptide Bioscience’s lead drug candidate RP-185 was the subject of an invited poster presentation at this month’s annual meeting of the American Association for Cancer Research (AACR). The AACR meeting is the year’s premier venue for announcing the most significant new research into the etiology and treatment of cancer. The title […]

Contact Riptide Bioscience

Riptide Bioscience welcomes inquiries from potential partners, licensees, and investors interested in our development programs and proprietary drug candidates. To explore collaboration or investment opportunities, please contact us at info@riptidebio.com.

Dr. Donald Kennedy†

Founding Advisor · In Memoriam

Prior to his untimely passing, Dr. Kennedy was a founding advisor and shareholder in Riptide Bioscience, and we strive to maintain the scientific rigor and higher objectives he inspired.  Dr. Kennedy was a noted neurobiology research scientist prior to chairing Stanford University’s Department of Biology and founding its Program in Human Biology.  He went on to serve as the US FDA Commissioner, later returning to Stanford as provost and ultimately University President.  Subsequently he served as editor-in-chief of Science.

Dame Carol Black

Board of Advisors

Dame Carol Black is a world-renowned expert in rheumatology, who served as Medical Director of the Royal Free Hospital at University College London, where she established Europe’s largest center for both scleroderma research and treatment.  Later she served as President of the Royal College of Physicians, and served as the UK government’s National Director for Health and Work.  She is co-president of the UK government organization focusing on the consequences of musculoskeletal disorders, and led the government’s Independent Review of Drugs.

Dr. Frank McCormick

Board of Advisors

Dr. Frank McCormick is among the world’s top cancer researchers, and received the first Stephenson Global Prize for his groundbreaking cancer discoveries.  Dr. McCormick’s pioneering work uncovered how mutations in the KRAS gene, present in more than 90% of pancreatic ductal adenocarcinomas (PDAC), disrupt the body’s natural ability to regulate cell growth. His discoveries have been foundational to the development of therapies targeting KRAS, a goal once thought unattainable.

Dr. Leonard Post

Board of Directors

Dr. Leonard Post has more than 30 years of experience with all stages of drug development, from early discovery through FDA approval.  Previously he served as Senior Vice President of Research and Development at Onyx Pharmaceuticals from 2000 to 2006. In this role, he was responsible for the co-development of Nexavar through to FDA approval for renal cancer. Onyx was sold to Amgen for $10 billion. Subsequently he served as Chief Scientific Officer and Co-Founder of LEAD Therapeutics (sold to BioMarin for $100M), and remained at BioMarin as Chief Scientific Officer.

Dr. Clayton Yates

Principal Scientist

Dr. Yates, Professor of Oncology, Pathology and Urology at Johns Hopkins University, has administered numerous grant awards from the National Cancer Institute and the Congressionally Directed Medical Research Program at the Department of Defense, and is a frequent invited speaker at national and international conferences focusing on prostate and breast cancer. Dr. Yates’ research focuses on how the tumor microenvironment influences epigenetic regulators, which can cause tumor cells to undergo epithelial to mesenchymal transition (EMT), and promote metastasis.

Dr. L. Edward Clemens

Principal Scientist

Dr. Clemens is a biologist and pharmacologist with 35 years’ experience in drug development, including the first identification of antagonists useful for controlling estrogen-dependent cancers. Dr. Clemens has led research teams at companies including Parke-Davis, Scios, and Metabolex, including the team that prepared data for the IND and ultimate approval of a recombinant form of human natriuretic peptide for congestive heart failure.

Dr. Jesse Jaynes

Principal Scientist

Dr. Jaynes is a leading biochemist specializing in peptide design, and has served as Chief Scientific Officer at two previous companies. As documented in >120 peer-reviewed publications and >60 patents, the Jaynes Lab was first in the world to demonstrate antiprotozoal, plant disease resistance, and anticancer activity for designed lytic peptides both in vitro and in vivo. In agriculture, Dr. Jaynes’ antimicrobial peptides have been licensed by US Sugar / Tropicana for use in citrus crop protection.

Kathryn Woodburn, Ph.D.

Senior Vice President, Translational Sciences

Translational development executive with 25+ years driving programs from discovery through IND, clinical development, and regulatory approval. Known for shaping development strategy, integrating cross‑functional scientific disciplines, and delivering registration‑ready data packages. Career includes leadership roles at Life Edit Therapeutics (ElevateBio), Avalanche/Adverum (acquired by Eli Lilly), Affymax, and Pharmacyclics (AbbVie), complemented by a consulting practice supporting translational drug development, and regulatory strategy across gene therapy, gene editing, regenerative medicine, ophthalmology, pain, oncology, hematology, arthritis, inflammation, infection and drug delivery. Author of 70+ peer‑reviewed publications and inventor on 10 patents.

Henry Lopez, Ph.D.

EVP — Operations

Dr. Lopez is an executive with both hands-on and management expertise in preclinical development, focusing particularly on execution of a wide variety of in vitro and in vivo assays.  Dr. Lopez managed laboratories at Xoma, Glycomed, and ultimately Parke-Davis/Pfizer as Director of its Phenotyping Core.  He went on to found MuriGenics, a large Contract Research Organization, servicing publicly-held and privately-held pharmaceutical companies worldwide.  Dr. Lopez is also an Associate Professor at the Division of Medicine, University College London.

Charles Garvin

CEO

Mr. Garvin, a seasoned CEO and technology investor, has a BA and JD from Harvard University, and did PhD study at Oxford University as a Rhodes Scholar. He has been Chairman, CEO, or controlling shareholder at a number of tech and biotech companies during a 40-year career. Mr. Garvin served as an officer and member of the Board of Directors at the Boston Consulting Group, a leading strategy consulting organization, and was one of the original principals of the Beta Group, a seed capital firm which has incubated several successful medical technology companies. Subsequently Mr. Garvin has served as Chairman or represented controlling interests in companies of up to $350 million in revenues, including TVC Communications, Riviera Trading, EK Holdings and Basic Industries. He is currently a Director of Tosk, Inc. (cancer chemotherapies) and Senior Advisor to SanBio (stem cell therapies).